<DOC>
	<DOCNO>NCT02527733</DOCNO>
	<brief_summary>The efficacy anti-vascular endothelial growth factor ( VEGF ) therapy branch retinal vein occlusion ( BRVO ) show , effect retinal sensitivity fully investigate . The purpose study compare change retinal sensitivity ranibizumab therapy combination therapy ranibizumab laser photocoagulation eye BRVO .</brief_summary>
	<brief_title>Retinal Sensitivity BRVO After Anti-VEGF Therapy</brief_title>
	<detailed_description />
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Treatment naive patient branch retinal vein occlusion visual acuity le 1.0 macular edema 250 micrometer foveal thickness . Patients history treatment branch retinal vein occlusion , possibility pregnancy , allergy ranibizumab , intraocular infection , severe inflammation exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>